路易体痴呆

McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100.全文  摘要

Expert Panel on Neurological Imaging; Moonis G, Subramaniam RM, Trofimova A, et al. ACR Appropriateness Criteria® dementia. J Am Coll Radiol. 2020 May;17(5s):S100-12.全文  摘要

Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020 Feb;19(2):157-69.全文  摘要

O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017 Feb;31(2):147-68. 摘要

Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504.全文  摘要

Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016 May 1;173(5):543-6.全文  摘要

1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100.全文  摘要

2. Hemminghyth MS, Chwiszczuk LJ, Rongve A, et al. The cognitive profile of mild cognitive impairment due to dementia with Lewy bodies - an updated review. Front Aging Neurosci. 2020 Dec 23;12:597579.全文  摘要

3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.

4. American Psychiatric Association. DSM-5-TR neurocognitive disorders supplement. Updated excerpts for delirium codes. Major and mild neurocognitive disorders. Oct 2022 [internet publication].全文

5. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022 Feb;7(2):e105-25.全文  摘要

6. Expert Panel on Neurological Imaging; Moonis G, Subramaniam RM, Trofimova A, et al. ACR Appropriateness Criteria® dementia. J Am Coll Radiol. 2020 May;17(5s):S100-12.全文  摘要

7. Ferman TJ, Smith GE, Kantarci K, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology. 2013 Dec 3;81(23):2032-8. 摘要

8. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005 Nov;34(6):561-6.全文  摘要

9. Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci. 2016 Dec;18(4):437-46.全文  摘要

10. Mouton A, Blanc F, Gros A, et al. Sex ratio in dementia with Lewy bodies balanced between Alzheimer's disease and Parkinson's disease dementia: a cross-sectional study. Alzheimers Res Ther. 2018 Sep 12;10(1):92.全文  摘要

11. Rampello L, Cerasa S, Alvano A, et al. Dementia with Lewy bodies: a review. Arch Gerontol Geriatr. 2004 Jul-Aug;39(1):1-14. 摘要

12. Bogaerts V, Engelborghs S, Kumar-Singh S, et al. A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain. 2007 Sep;130(Pt 9):2277-91.全文  摘要

13. Ohara K, Takauchi S, Kokai M, et al. Familial dementia with Lewy bodies (DLB). Clin Neuropathol. 1999 Sep-Oct;18(5):232-9. 摘要

14. Rosenberg CK, Cummings TJ, Saunders AM, et al. Dementia with Lewy bodies and Alzheimer's disease. Acta Neuropathol. 2001 Dec;102(6):621-6. 摘要

15. Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet. 2014 Dec 1;23(23):6139-46全文  摘要

16. Samuel W, Galasko D, Masliah E, et al. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol. 1996 Jan;55(1):44-52. 摘要

17. Weisman D, Cho M, Taylor C, et al. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology. 2007 Jul 24;69(4):356-9. 摘要

18. Armstrong MJ. Advances in dementia with Lewy bodies. Ther Adv Neurol Disord. 2021 Nov 23;14:17562864211057666.全文  摘要

19. Galvin JE. Improving the clinical detection of lewy body dementia with the lewy body composite risk score. Alzheimers Dement (Amst). 2015 Sep 1;1(3):316-24.全文  摘要

20. Ryu HJ, Kim M, Moon Y, et al. Validation of the Korean version of the Lewy Body Composite Risk Score (K-LBCRS). J Alzheimers Dis. 2017;55(4):1395-401. 摘要

21. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004 Jan 27;62(2):181-7. 摘要

22. Chan PC, Lee HH, Hong CT, et al. REM sleep behavior disorder (RBD) in dementia with Lewy bodies (DLB). Behav Neurol. 2018 Jun 19;2018:9421098.全文  摘要

23. Roguski A, Rayment D, Whone AL, et al. A neurologist's guide to REM sleep behavior disorder. Front Neurol. 2020 Jul 8;11:610.全文  摘要

24. Fahn S, Elton RL; UPDRS program members. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, et al, eds. Recent developments in Parkinson’s disease. Vol 2. Florham Park, NJ: Macmillan Healthcare; 1987:153-63.

25. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308-14. 摘要

26. Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13(5):PCC.11r01190.全文  摘要

27. Quigley H, Colloby SJ, O'Brien JT. PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry. 2011 Oct;26(10):991-9. 摘要

28. Bonanni L, Franciotti R, Nobili F, et al. EEG markers of dementia with Lewy bodies: a multicenter cohort study. J Alzheimers Dis. 2016 Oct 18;54(4):1649-57. 摘要

29. Janvin C, Larsen J, Salmon D, et al. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with Lewy bodies and Alzheimer's disease. Mov Disord. 2006 Mar;21(3):337-42. 摘要

30. Tiraboschi P, Salmon D, Hansen L, et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? 2006 Mar;129(Pt 3):729-35.全文  摘要

31. Burn DJ. Cortical Lewy body disease and Parkinson's disease dementia. Curr Opin Neurol. 2006 Dec;19(6):572-9. 摘要

32. Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020 Feb;19(2):157-69.全文  摘要

33. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. Jun 2018 [internet publication].全文

34. Salmon DP, Galasko D, Hansen LA, et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn. 1996 Jul;31(2):148-65. 摘要

35. Watson R, Blamire AM, O'Brien JT. Magnetic resonance imaging in Lewy body dementias. Dement Geriatr Cogn Disord. 2009;28(6):493-506.全文  摘要

36. Stinton C, McKeith I, Taylor JP, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015 Aug 1;172(8):731-42.全文  摘要

37. Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):135-43.全文  摘要

38. Chiong W, Tsou AY, Simmons Z, et al. Ethical considerations in dementia diagnosis and care: AAN position statement. Neurology. 2021 Jul 13;97(2):80-9.全文  摘要

39. Taylor LP, Besbris JM, Graf WD, et al. Clinical guidance in neuropalliative care: an AAN position statement. Neurology. 2022 Mar 8;98(10):409-16.全文  摘要

40. Walsh SC, Murphy E, Devane D, et al. Palliative care interventions in advanced dementia. Cochrane Database Syst Rev. 2021 Sep 28;(9):CD011513.全文  摘要

41. Iverson DJ, Gronseth GS, Reger MA, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Apr 20;74(16):1316-24.全文  摘要

42. Howell M, Avidan AY, Foldvary-Schaefer N, et al. Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2023 Apr 1;19(4):759-68.全文  摘要

43. Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):36-42.全文  摘要

44. Hepburn K, Lewis M, Tornatore J, et al. The Savvy Caregiver program: the demonstrated effectiveness of a transportable dementia caregiver psychoeducation program. J Gerontol Nurs. 2007 Mar;33(3):30-6. 摘要

45. Griffiths PC, Kovaleva M, Higgins M, et al. Tele-Savvy: an online program for dementia caregivers. Am J Alzheimers Dis Other Demen. 2018 Aug;33(5):269-76.全文  摘要

46. Kally Z, Cote SD, Gonzalez J, et al. The Savvy Caregiver Program: impact of an evidence-based intervention on the well-being of ethnically diverse caregivers. J Gerontol Soc Work. 2014;57(6-7):681-93. 摘要

47. Connors MH, Quinto L, McKeith I, et al. Non-pharmacological interventions for Lewy body dementia: a systematic review. Psychol Med. 2018 Aug;48(11):1749-58.全文  摘要

48. Orgeta V, Leung P, Del-Pino-Casado R, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2022 Apr 25;(4):CD009125.全文  摘要

49. Bahar-Fuchs A, Martyr A, Goh AM, et al. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019 Mar 25;(3):CD013069.全文  摘要

50. Abraha I, Rimland JM, Trotta FM, et al. Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. BMJ Open. 2017 Mar 16;7(3):e012759. [Erratum in: BMJ Open. 2017 Jul 17;7(7):e012759corr1.]全文  摘要

51. van der Steen JT, Smaling HJ, van der Wouden JC, et al. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev. 2018 Jul 23;(7):CD003477.全文  摘要

52. Leng M, Zhao Y, Wang Z. Comparative efficacy of non-pharmacological interventions on agitation in people with dementia: a systematic review and Bayesian network meta-analysis. Int J Nurs Stud. 2020 Feb;102:103489. 摘要

53. O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017 Feb;31(2):147-68. 摘要

54. Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504.全文  摘要

55. McKeith IG, Mosimann UP. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat Disord. 2004 May;10(suppl 1):S15-8. 摘要

56. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012 Sep;19(9):1159-79.全文  摘要

57. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;(3):CD003154.全文  摘要

58. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016 May 1;173(5):543-6.全文  摘要

59. Yunusa I, Alsumali A, Garba AE, et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open. 2019 Mar 1;2(3):e190828.全文  摘要

60. Tariot PN, Cummings JL, Soto-Martin ME, et al. Trial of pimavanserin in dementia-related psychosis. N Engl J Med. 2021 Jul 22;385(4):309-19.全文  摘要

61. Boeve BF, Silber MH, Parisi JE, et al. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004 Sep;17(3):146-57.全文  摘要

62. Watt JA, Goodarzi Z, Veroniki AA, et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis. BMJ. 2021 Mar 24;372:n532.全文  摘要

63. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Oct;9(10):969-77. 摘要

64. Kurtz AL, Kaufer DI. Dementia in Parkinson's disease. Curr Treat Options Neurol. 2011 Jun;13(3):242-54. 摘要

65. Substance Abuse and Mental Health Services Administration. Emergency department visits involving nonmedical use of the anti-anxiety medication alprazolam. The CBHSQ Report. Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2014.全文

66. Desai AK, Grossberg GT. Recognition and management of behavioral disturbances in dementia. Prim Care Companion J Clin Psychiatry. 2001 Jun;3(3):93-109.全文  摘要

67. Molloy S, McKeith IG, O'Brien JT, et al. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005 Sep;76(9):1200-3.全文  摘要

68. Lucetti C, Logi C, Del Dotto P, et al. Levodopa response in dementia with Lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010 Sep;16(8):522-6. 摘要

69. Davies N, Barrado-Martín Y, Vickerstaff V, et al. Enteral tube feeding for people with severe dementia. Cochrane Database Syst Rev. 2021 Aug 13;(8):CD013503.全文  摘要

70. Stefani A, Santamaria J, Iranzo A, et al. Nelotanserin as symptomatic treatment for rapid eye movement sleep behavior disorder: a double-blind randomized study using video analysis in patients with dementia with Lewy bodies or Parkinson's disease dementia. Sleep Med. 2021 May;81:180-7.全文  摘要

71. Lang FM, Kwon DY, Aarsland D, et al. An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). Alzheimers Dement (NY). 2021;7(1):e12171.全文  摘要

72. Biglan K, Munsie L, Svensson KA, et al. Safety and efficacy of mevidalen in Lewy body dementia: a phase 2, randomized, placebo-controlled trial. Mov Disord. 2022 Mar;37(3):513-24.全文  摘要

73. ClinicalTrials.gov. Cognitive effects of oral p38 alpha kinase inhibitor neflamapimod in dementia with Lewy bodies (AscenD-LB). NCT04001517. 2 November 2021 [internet publication].全文

74. Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015 Sep 22-29;314(12):1242-54.全文  摘要

75. Magierski R, Sobow T, Schwertner E, et al. Pharmacotherapy of behavioral and psychological symptoms of dementia: state of the art and future progress. Front Pharmacol. 2020 Jul 31;11:1168.全文  摘要

76. ClinicalTrials.gov. The effect of cannabis on dementia related agitation and aggression. NCT03328676. 8 March 2022 [internet publication].全文

77. Alagiakrishnan K, Bhanji RA, Kurian M. Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic review. Arch Gerontol Geriatr. 2013 Jan-Feb;56(1):1-9. 摘要

78. British Geriatrics Society. Driving with dementia or mild cognitive impairment: consensus guidelines for clinicians. 10 January 2019 [internet publication].全文